The role of IFN-γ/CXCL10 axis in Mycoplasma pneumonia infection

doi:10.21203/rs.3.rs-4894277/v1

Download PDF

Research Article

The role of IFN-γ/CXCL10 axis in Mycoplasma pneumonia infection

https://doi.org/10.21203/rs.3.rs-4894277/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Background

Mycoplasma pneumoniae caused lower respiratory tract infection, is highly prevalent in children and can be extremely dangerous for their health and well-being. However, the pathogenesis of this infection is complicated and thus has not been thoroughly studied.

Methods

ELISAs were used to analyze the expression levels of cytokines such as CXCL10 and IFN-γ in the peripheral blood and bronchoalveolar lavage fluid (BALF) of children with Mycoplasma pneumoniae pneumonia (MPP) and healthy controls. Western blot, RT-PCR, and flow cytometry were used to explore the effects of JAK-STAT1 signaling pathway on CXCL10 expressions.

Results

We discovered that, compared to control children, MPP patients expressed significantly higher levels of CXCL10 both in the peripheral blood and BALF, which was positively correlated with serum IFN-g and IgM levels as well as clinical presentations like days of hospitalization and fever duration. Moreover, numbers of macrophages, predominantly with a M1 phenotype, were significantly increased in BALFs of children of MPP. In vitro, coculture with IFN-γ or activated CD4⁺ Th1 cells significantly promoted CXCL10 expressions in THP-1 derived macrophages, which was largely reversed by siRNA-mediated down regulation of STAT1. In addition, IFN-g-stimulated macrophages greatly promoted the trans-migration of Th1 cells.

Conclusions

our data showed that Th1 cells-derived IFN-γ augments CXCL10 production in macrophages via the JAK-STAT1 pathway, which subsequently recruits more immune cells like Th1 cells into the infection sites, thereby constituting a positive feedback loop and aggravating the type I inflammatory responses in MPP patients.

Mycoplasma pneumoniae

CXCL10

IFN-γ

Lower respiratory tract infections (LRTIs), with outbreaks mostly occurring in the fall and winter, are the major cause of morbidity and mortality in children. Among LRITs, community-acquired pneumonia (CAP) is the most common cause of hospitalization/death for children in developed/developing countries, respectively [1, 2]. In children over the age of five, MPP accounts for over 40% of cases of CAP [3]. The most common clinical presentations of MPP are fever, dyspnea, and cough, sometimes accompanied by runny nose, nasal congestion, chest pain, wheezing, and pharyngitis [4, 5], in addition to a variety of extrapulmonary manifestations like gastrointestinal and skin disorders [6]. Massive pleural effusions may also be linked to severe instances of MPP. Despite that tetracyclines and fluoroquinolones are effective in reducing the duration of fever and respiratory symptoms of MPP, many questions regarding their safety and effectiveness remain undetermined [7, 8].

After being inhaled, MPP easily and closely attaches to ciliated cells of the respiratory epithelium via special attaching organelles due to the absence of a cellular wall structure, and thereby exchange chemicals/proteins with host cells efficiently. Community-acquired respiratory distress syndrome (CARDS) toxin, a multifunctional protein with 591 amino acids (aa), is the primary virulence factor of MPP. Upon binding to surfactant protein A and entering into host cells through lattice protein-mediated endocytosis, CARDS utilizes the host's acidic pH and vesicular ATPase proton pump to exert its biological function, leading to the production of proinflammatory cytokines and the acute cellular inflammatory response [9] .

It has been demonstrated that both the innate and adaptive immune systems participate in MPP infections, and thus the magnitude of immune responses highly correlate to the disease severity. Upon MPP infection, alveolar macrophages ingest the pathogen and present it to cognate T cells, eventually triggering the production of cytokines and chemokines, which will recruit more immune cells into the infection sites to amplify the inflammatory responses. The M1 and M2 are two major types of macrophages. LPS and IFN-γ induce the differentiation of M1 macrophages, which produce chemokines like CXCL1, CXCL5, CXCL9, CXCL10, CCL3, and CCL19, as well as cytokines including IL-6, IL-8, IL-10, IL-1β, and TNF-α [10, 11]. By contrast, M2 macrophages, normally differentiated in the presence of IL-4, produce a distinct set of chemokines, such as CCL1, CCL14, CCL17, and CCL24 [11]. Amongst these soluble factors, CXCL10, a member of the CXC chemokine family produced by M1 macrophages, plays a critical role in the recruitment and activation of neutrophils, NK cells and lymphocytes. As such, serum levels of CXCL10 have been shown to correlate with MPP infection and could serve as a useful biomarker to monitor MPP progression in clinics [12, 13]. Nevertheless, how the production of CXCL10 is modulated in children with MPP remains elusive and thus warrants additional investigations.

It has been reported that Dickkopf-1 (DKK1) may be effective in reducing the MPP-induced massive secretion of mucin 5AC (MUC5AC) by inhibiting the JAK/STAT signaling pathway in a mouse model of MPP [14, 15]. Moreover, IFN-γ induces CXCL10 through activation of the JAK/STAT1 signaling in many immune disorders [16, 17]. STAT1 and CXCL10 promote the polarization of M1-type macrophages [18]. Therefore, we speculated that IFN-γ may promote CXCL10 expression by M1-type macrophages through the JAK/STAT1 pathway, and thereby exacerbates inflammatory responses in the lungs of patients with MPP. In this study, we collected peripheral blood and BALF in children with MPP, and analyzed the correlation between CXCL10 levels and other immunological/clinical parameters. In addition, we also deciphered pathways underlying the IFN-γ-induced CXCL10 productions in macrophages in vitro. Our findings may be helpful for the diagnosis and tailored treatment/management of children with MPP.

Patients

The study included 122 hospitalized children with a diagnosis of MPP in the Department of Respiratory Medicine at Children's Hospital of Soochow University during March to November 2023, among whom 63 (51.64%) were males and 59 (48.36%) were females. 48 cases were categorized as group A to determine the relationship between serum CXCL10 levels and pathogen loads in nasopharyngeal aspirates as well as other clinical parameters within 24 h of hospitalization; 74 patients with IFN-γ and CXCL10 levels in BALF were selected as group B to investigate the correlation of IFN-γ/CXCL10 and immunoinflammatory injury in the lungs. Peripheral blood from 40 children who had physical examinations at the Department of Child Health outpatient clinic and BALF from 14 children who underwent emergency surgery in the Ear Nose and Throat (ENT) Department of our hospital within the same period as mentioned above served as control samples. Children in the control group were in good health over the course of last four weeks before samples were taken, and had no history of drug use, respiratory conditions such as airway deformities, and cardiac, hepatic, renal, hematologic, or metabolic illnesses. The study was reviewed and approved by the Ethics Committee of the Children’s Hospital of Soochow University (2019LW014). Written informed consent to participates of this study was provided and signed by their legal guardian/next of kin.

Diagnostic criteria

(1) CAP: CAP is defined as an acute infection of the parenchyma or interstitial areas of the lungs. This type of infection frequently manifests as fever and cough, along with signs like increased respiration, wet lung rhonchi, and abnormal changes on chest imaging in clinics. (2) MPP: positive MPP-specific immunoglobulin (IgM) in peripheral blood and MPP DNA in nasopharyngeal aspirate or BALF ≥ 1.0×10⁴ copies/ml as determined by qPCR.

Exclusion criteria

(1) recurrent infections of the respiratory tract; (2) clinical signs and supporting data of typically bacterial pneumonia; (3) high-risk factors or clinical and imaging features of fungal pneumonia; (4) positive antigen or nucleic acid test for NPA or BALF virus; (5) presence of congenital disorders or birth defects; (6) respiratory diseases, including metabolic, cardiac, hepatic, renal, and other systemic abnormalities; (7) receiving experimental medications or devices.

Collection of clinical data

The electronic medical record system was used to gather the children's clinical data, including the age, sex, cough, fever duration/peaks, number of hospital days, pulmonary symptoms, and imaging, etc. White blood cells (WBC), neutrophil percentages (N%), platelets (PLT), lactate dehydrogenase (LDH), C-reactive protein (CRP), immunoglobulins (IgA/IgG/IgM), lymphocyte subpopulations, and so on were measured in the laboratory.

Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) analysis

After the extraction of total cellular RNA from cultured cells using Trizol reagent (Invitrogen), 1 µg of RNA was reverse transcribed to cDNA with the M-MLV Reverse Transcriptase (ELK Biotechnology), and then qPCR was conducted by using the QuFast SYBR Green PCR Master Mix (ELK Biotechnology).

The primer sequences were as follows: CXCL10, Antisense 5′-GTAAATTCTTGATGGGCCTTCG-3′, and Sense5′-CCATTCTGATTTGCTGCCTTAT-3′; β-Actin, Antisense5′-CTGGAAGGTGGACAGCGAGG-3′, and Sense 5′- TGACGTGGACATCCGCAAAG-3′; siSTAT1, Antisense 5′-TCTACAGAGCCCACTATCCGAG-3′, and Sense 5′- ACTTTCCCTGACATCATTCGC-3′.

Protein Chip

Peripheral blood samples from the refractory Mycoplasma pneumoniae pneumonia (RMPP), non-refractory Mycoplasma pneumoniae pneumonia (NRMPP), and healthy patients were collected. Peripheral Blood Protein Microarray High-Throughput Protein Screening Technology and Results Provided by Ray Biotech Ray Biotech (Guangzhou) Co.

Cell culture

THP-1 cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, 1% sodium pyruvate, 1% HEPES, and 50 µM b-mercaptoethanol at 37°C in a humidified atmosphere of 5% CO₂. Macrophages were obtained by culturing THP-1 cells with phorbol ester (PMA, 50 ng/ml) for 24 hours. Subsequently, these THP-1 derived M1-type macrophages were stimulated with different concentrations of IFN-γ, and the expression levels of CXCL10 were detected at different time points (3, 6, and 9 h). CD4⁺ T cells were isolated from healthy human peripheral blood by magnetic beads (the Direct Human CD4⁺ T Cell Isolation Kit, STEMCELL Technologies, Vancouver, Canada), and were stimulated in vitro with anti-CD3/28 in the presence of IL-2 & IL-12 for 4 days to induce the differentiation toward Th1 cells.

ELISA

Levels of CXCL10 and IFN-γ in the peripheral blood and/or BALF of MPP and control groups were measured by precise ELISA kits in accordance with the manufacturer's instructions (Asahi Kok Hing Biotech Co., Ltd., Suzhou, China).

Flow cytometry

Percentages of macrophages, lymphocytes, and neutrophils in the BALF of children were determined by flow cytometer (Beckman Coulter, USA). The following antibodies were used: anti-CD16 (clone GRM1), anti-CD64 (clone 10.1), anti-CD45 (clone F10-89-4) and anti-CD163 (clone GHI/61).

Western blot

Western blot was carried out utilizing the conventional SDS-PAGE separation method. The cells were rinsed twice with a pre-cooled PBS solution, and then lysed in RIPA buffer containing protease inhibitors on ice for 30 minutes. A 10% SDS-PAGE gel was used for electrophoresis, followed by blotting onto a PVDF membrane. After blocking with 5% milk for an hour, the membrane was incubated with the first antibody overnight at 4°C in a shaker, and then with the HRP-conjugated goat anti-mouse IgG (secondary antibody) at room temperature for 1 h with three TBST washes in between. The immunoreactive protein bands were visualized in a chemiluminescence instrument.

Transfection

THP-1 cells were seeded in 6-well plates (5×10⁵/well) and cultured overnight to reach the confluency of ~ 80% before the transfections. siRNA-lipofectamine 2000 mix were prepared according to the manufacturer’s instruction. After the addition of siRNA-lipofectamine 2000 mix, cells were incubated for a further 24 h before analysis.

Transwell assays

Transwells were inserted into the 24-well culture plates. Th1 cells (2×10⁴ cells/ml) were placed in the upper chamber of the Transwell insert, while THP-1-derived macrophages, pre-treated with IFN-γ (1 ng/ml) for 24 h to induce CXCL10 productions, were seeded in the lower compartment. In some cases, STAT1-targeting siRNA was added into the low chamber. After 3 h, the number and morphology of migrated Th1 cells was determined by smear staining.

Statistical analysis

All statistical analyses were performed with the software SPSS 21.0. Count data were expressed as percentages or rates; normally distributed measures were expressed as mean ± standard deviation (SD), and Spearman's correlation analysis was carried out as well. P ≤ 0.05 was regarded as statistically significant.

Demographic data, clinical and laboratory characteristics

A total of 122 children in the MPP group and 54 controls were enrolled in the present study. The demographic data, clinical and laboratory characteristics of children are shown in Table 1. In the MPP group, the mean age of the children was 6.86 ± 0.25 years, with 63/59 males/females accounting for 51.6%/48.4%, respectively. 11 patients (9.01%) had pleural effusion, and 29 (23.77%) had lobar pneumonia. Clinically, children with pneumonia mainly manifested with cough and fever, with an average fever duration of 7.6 ± 0.38 days and fever peak of 39 ± 0.34℃. The mean age of the control group was 3.37 ± 0.37 years, with 38 males (70.4%) and 16 females (29.6%).

TABLE 1 Demographic data and clinical characteristics of patients enrolled in this study

Altered CXCL10 protein levels in children with MPP

We first performed a protein chip analysis by using 3 blood samples from the groups of refractory Mycoplasma pneumoniae pneumonia (RMPP), non-refractory Mycoplasma pneumoniae pneumonia (NRMPP), and healthy patients to screen for differentially expressed proteins (DEPs) among these groups. Our data revealed that CXCL10 was the most significantly upregulated proteins in MPPs (P < 0.05; Figure 1A). Moreover, ontology analysis showed that most DEPs related to the cytokine-cytokine receptor interaction pathway, such as cell migration/chemotaxis, chemokine-mediated signaling pathway and CXCR3 chemokine receptor binding (Figures 1B). Then we used KEGG analysis to predict which the JAK/STAT signaling pathway would involve CXCL10 in the pathogenesis of NRMPP or RMPP (Figures 1C).

Clinical significance of IFN-γ/CXCL10 in the peripheral blood and BALF

In line with data obtained in protein chip analysis, the expression levels of inflammatory factors CXCL10 and IFN-γ were significantly elevated in the peripheral blood and BALF of MMP patients than those in controls (Figure 2A). Moreover, levels of CXCL10 were significantly higher in the BALF as compared to that in peripheral blood of MPP patients (Figure 2B). Notably, blood CXCL10 levels were positively correlated with days of hospitalization (r = 0.565, P < 0.05), fever duration (r = 0.341, P < 0.05) and serum IFN-g levels (r = 0.576, P < 0.0001), and BALF CXCL10 levels were positively correlated with total IgM in blood (r = 0.365, P < 0.05) in the MPP group (Figure 2C). In addition, the numbers of neutrophils and macrophages in the alveolar lavage fluid of MPP patients were remarkably increased as compared to those in the control group, and the majority (> 80%) of macrophages in BALF of MPP patients exhibited a M1-polarized phenotype (CD16⁺CD64⁺CD163^-) (Figure 2D&E). In line with its biological function, CXCL10 levels showed a significant correlation with neutrophil/macrophages numbers in BALF (Figure 2F).

STAT1 down-regulation inhibits IFN-g-induced CXCL10 expression in M1-type monocytic macrophages

IFN-γ promoted the mRNA and protein levels of CXCL10 in THP-1-derived macrophages in a dose-dependent fashion in all time points (3, 6, and 9 h) analyzed (P < 0.05, Figure 3A&B), accompanied with the increased phosphorylation of STAT1 (Figure 3C), indicating that IFN-g induces CXCL10 via STAT1. Indeed, siRNA-mediated downregulation of STAT1 significantly diminished the ability of activated Th1 cells (Figure 3D) or IFN-g (Figure 3E) to elevate CXCL10 expressions in THP-1-derived macrophages as determined by western blot, qPCR and ELISA. Moreover, si-RNA mediated downregulation of STAT1 repressed the ability of THP-1-derived macrophages to activate Th1 cells, as evidenced by the significantly reduced IFN-g levels in culture supernatants (Figure 3F).

CXCL10 promotes the migration of Th1 cells

The results we showed above indicated that IFN-g and/or activated Th1 cells promotes CXCL10 productions in macrophages via STAT1. To determine the reciprocal effect of STAT1-induced CXCL10 in macrophages on Th cells, we next conducted transwell experiments. The addition of IFN-g in the lower chamber greatly promoted the migration of Th1 cells, which was significantly diminished by siRNA-mediated knockdown of STAT1 (Figure 4), indicating that macrophage-derived CXCL10, triggered by the IFN-g/STAT1 axis, induces the transmigration of Th1 cells.

Together, our data indicate that IFN-g promotes the production of CXCL10 in macrophages via STAT1. Subsequently, CXCL10 recruits more IFN-g-producing Th1 cells into the inflammatory sites, thereby constituting a vicious circle that exacerbates proinflammatory immune responses and tissue damages in patients with MPP infections

Mycoplasma pneumoniae is one of the primary pathogens that cause chronic respiratory diseases in humans. In recent years, the incidence of MPP has been rising, and in some cases, it has even become a serious or fatal condition in children [19]. The pathogenesis of MPP is complicated and can be classified into two main categories: extrapulmonary and intrapulmonary modes of infection. Intrapulmonary infections may relate to adhesion proteins, nutrient depletion, toxins, oxidative damage, inflammatory damage, and immune evasion. By contrast, extrapulmonary infections seem to mainly manifest as immune-mediated direct injury caused by inflammatory cytokines, or vascular occlusion as a result of thrombosis/vasculitis formation [20, 21]. Upon MPP infection, the opsonization effect of antibodies/complements may induce a cytokine storm by activating various immune cells, including neutrophils, macrophages and lymphocytes, and thereby leads to serious tissue damages in the lungs. Thus, studies on the inflammatory responses induced by Mycoplasma pneumoniae as well as the underlying molecular mechanisms will benefit the diagnosis and treatment of MPP patients clinically.

We herein found that the expression levels of CXCL10 were significantly elevated in both the peripheral blood and BALF of MPP patients as compared to those in controls. Moreover, levels of CXCL10 were higher in BALF than that in the peripheral blood of patients with MPP, pointing to an ongoing local production at infection sites. Indeed, CXCL10 was positively correlated with clinical manifestations and laboratory indexes, including days of hospitalization, fever duration, as well as serum IFN-g and IgM levels. These findings are consistent with previous studies showing that elevated levels of CXCL10 were linked to disease duration, progression, and severity in patients with MPP or COVID-2019 [22–24]. As such, CXCL10 has been used as a clinic maker for the diagnosis and/or prognosis of various disorders.

It has been shown that the levels of cytokines in blood samples from children, including IL-4, IFN-γ, IL-17, TNF-α, and CXCL10, were significantly increased in cases of MPP patients as compared to those in the control group [25–27]. Our study confirms and expands these findings by showing the significantly increased numbers of neutrophils and M1-type macrophages in the BALF of kids correlate to CXCL10 levels in BALF. It is thus conceivable that high local CXCL10 levels contribute, at least partially, to the recruitment of immune cells into BALF of patients with MPP. Despite the increase of both IL-4 (a signature cytokine of Th2 cells) and IFN-g (a hallmark cytokine of Th1 cells) in MPP patients, the M1-phenotype dominated macrophages in BALF suggest the Th1-type immune response prevails in respiratory tracts/lungs of MPP patients. In support of this notion, it has been shown that IFN-g induces CXCL10 expressions in a variety of cell types, including monocytes, endothelial cells and dendritic cells in autoimmune diseases. Upon binding to CXCR3, CXCL10 augments the migration/infiltration of CD8⁺ and Th1-type CD4⁺ effector T cells into the infection/inflammatory tissues [28, 29]. Given that levels of CXCL10 are positive correlated with IFN-g levels or with leukocytes numbers in BALF of MPP patients, and that IFN-γ stimulates M1-type macrophages to produce CXCL10, which subsequently promotes the migration of Th1 cells, we speculate that the reciprocal regulation of macrophages and Th1 cells, partially mediated via IFN-g and CXCL10, amplifies the type 1 immune responses and thereby aggravates tissue damages in respiratory tracts of patients with MPP.

The JAK-STAT1 signaling pathway participates multiple cytokine signalings and thus is important for our body's immune responses[27]. Despite that inflammatory responses in mouse lung tissues were attenuated by repression of the JAK2/STAT1-STAT3 signaling [15], the role of JAK-STAT1 signaling pathway in human MPP infections has not been thoroughly studied. Our data presented here showed that siRNA-mediated downregulation of STAT1 not only significantly diminished IFN-g induced CXCL10 production in macrophages, but also hampered the ability of macrophages to promote IFN-g production and migration of cocultured CD4⁺ Th1 cells. Thus, the IFN-g/STAT1/CXCL10 axis seems to dictate the reciprocal regulation between macrophages and Th1 cells, which forms a positive feedback loop to enhance both the numbers and the function of immune cells in inflammatory sites. Hence, the IFN-g/STAT1/CXCL10 axis may represent a potential target for treatment of MPP patients.

In conclusion, our data show that expression of CXCL10 is significantly elevated in MPP patients, and its expression levels positively correlate with INF-γ, leukocyte numbers in BLAFs and some clinical parameters. Moreover, our study indicates that IFN-g/STAT1/CXCL10 participates in the positive feedback loop that amplifies the inflammatory responses and exacerbates tissue damages in respiratory tracts of children with MPP infections.

IFN-γ	Interferon-γ
CXCL10	C-X-C motif chemokine ligand 10
BALF	Bronchoalveolar lavage fluid
MPP	Mycoplasma pneumoniae pneumonia
CARDS	Community-acquired respiratory distress syndrome
CAP	Community-acquired pneumonia
RMPP	Refractory Mycoplasma pneumoniae pneumonia
NRMPP	Non-refractory Mycoplasma pneumoniae pneumonia
DEPs	Differentially expressed proteins
BP	Biological process
CC	Cellular component
MF	Molecular function

Consent for publication

The legal guardian/next of kin agreed to participate in this study.

Ethics statement

The studies involving human participants were reviewed and approved by the Institutional Human Ethical Committee of Children’s Hospital of Soochow University with judgment’s reference number 2019LW014. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. Written informed consent was obtained from the individual(s), and minor(s)’ legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

Conflict of interest

The authors declare that they have no competing interests.

Funding

This work was funded by the National Natural Science Foundation of China (grant numbers 82370020, 82170012, 81970027, and 81971490), the Science and Technology Program of Suzhou (grant number SKY2022051), the Suzhou Gusu Health Talents Program Stratified Training (Key Talents) (grant number 2020058), and the Key Lab of Respiratory Disease of Suzhou (grant number SZS2017).

Author Contribution

YZ, FH and YZ conceived and designed the work. GD and TW did the literature search and figures preparation work. CZ, YY, RW and ZC revised and approved the manuscript.

Acknowledgement

Not applicable.

Data Availability

Availability of data and materialsDatasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, Stockmann C, Anderson EJ, Grijalva CG, Self WH et al: Community-Acquired Pneumonia Requiring Hospitalization among U.S. Children. New England Journal of Medicine 2015, 372(9):835-845.
Zar HJ, Barnett W, Stadler A, Gardner-Lubbe S, Myer L, Nicol MP: Aetiology of childhood pneumonia in a well vaccinated South African birth cohort: a nested case-control study of the Drakenstein Child Health Study. The Lancet Respiratory Medicine 2016, 4(6):463-472.
Atkinson TP, Waites KB: Mycoplasma pneumoniae Infections in Childhood. Pediatr Infect Dis J 2014, 33(1):92-94.
Waites KB, Talkington DF: Mycoplasma pneumoniaeand Its Role as a Human Pathogen. Clinical Microbiology Reviews 2004, 17(4):697-728.
Biagi C, Cavallo A, Rocca A, Pierantoni L, Antonazzo D, Dondi A, Gabrielli L, Lazzarotto T, Lanari M: Pulmonary and Extrapulmonary Manifestations in Hospitalized Children with Mycoplasma Pneumoniae Infection. Microorganisms 2021, 9(12).
Schildgen O, Søndergaard MJ, Friis MB, Hansen DS, Jørgensen IM: Clinical manifestations in infants and children with Mycoplasma pneumoniae infection. Plos One 2018, 13(4).
Yuan X, Liu J, Bai C, Niu W, Wang J, Li P, Liu H, Luo Y: Tigecycline in the treatment of fulminant Mycoplasma pneumoniae pneumonia non-responsive to azithromycin and fluoroquinolone. Medicine 2020, 99(28).
Ahn JG, Cho H-K, Li D, Choi M, Lee J, Eun B-W, Jo DS, Park SE, Choi EH, Yang H-J et al: Efficacy of tetracyclines and fluoroquinolones for the treatment of macrolide-refractory Mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis. BMC Infectious Diseases 2021, 21(1).
Ramasamy K, Balasubramanian S, Kirkpatrick A, Szabo D, Pandranki L, Baseman JB, Kannan TR: Mycoplasma pneumoniae CARDS toxin exploits host cell endosomal acidic pH and vacuolar ATPase proton pump to execute its biological activities. Scientific Reports 2021, 11(1).
Fan F, Lv J, Yang Q, Jiang F: Clinical characteristics and serum inflammatory markers of community-acquired mycoplasma pneumonia in children. The Clinical Respiratory Journal 2023, 17(7):607-617.
Lee Y-C, Chang C-H, Lee W-J, Liu T-Y, Tsai C-M, Tsai T-A, Tsai C-K, Kuo K-C, Chen C-C, Niu C-K et al: Altered chemokine profile in Refractory Mycoplasma pneumoniae pneumonia infected children. Journal of Microbiology, Immunology and Infection 2021, 54(4):673-679.
Li M, Chen Y, Li H, Yang D, Zhou Y, Chen Z, Zhang Y: Serum CXCL10/IP-10 may be a potential biomarker for severe Mycoplasma pneumoniae pneumonia in children. BMC Infectious Diseases 2021, 21(1).
Zhang Y, Ke J, Wang X, Xia S: Clinical characteristics and changes in serum CXCL10 and CXCL16 levels in patients with severe mycoplasma pneumonia. Medicine 2024, 103(16).
Shi J, Ma C, Hao X, Luo H, Li M: [Dickkopf-1 inhibits the secretion of MUC5AC induced by Mycoplasma pneumoniae P1-C in mouse lung epithelial cells]. Sheng Wu Gong Cheng Xue Bao 2023, 39(1):248-261.
Shi J, Ma C, Hao X, Luo H, Li M: Reserve of Wnt/β-catenin Signaling Alleviates Mycoplasma pneumoniae P1-C-induced Inflammation in airway epithelial cells and lungs of mice. Mol Immunol 2023, 153:60-74.
Panzer U, Zahner G, Wienberg U, Steinmetz OM, Peters A, Turner JE, Paust HJ, Wolf G, Stahl RA, Schneider A: 15-deoxy-Delta12,14-prostaglandin J2 inhibits INF-gamma-induced JAK/STAT1 signalling pathway activation and IP-10/CXCL10 expression in mesangial cells. Nephrol Dial Transplant 2008, 23(12):3776-3785.
Shi D, Li Y, Shi X, Yao M, Wu D, Zheng Y, Lin Q, Yang Y: Transcriptional expression of CXCL10 and STAT1 in lupus nephritis and the intervention effect of triptolide. Clin Rheumatol 2023, 42(2):539-548.
Liang T, Chen J, Xu G, Zhang Z, Xue J, Zeng H, Jiang J, Chen T, Qin Z, Li H et al: STAT1 and CXCL10 involve in M1 macrophage polarization that may affect osteolysis and bone remodeling in extrapulmonary tuberculosis. Gene 2022, 809:146040.
Kumar S: Mycoplasma pneumoniae: A significant but underrated pathogen in paediatric community-acquired lower respiratory tract infections. Indian Journal of Medical Research 2018, 147(1).
He J, Liu M, Ye Z, Tan T, Liu X, You X, Zeng Y, Wu Y: Insights into the pathogenesis of Mycoplasma pneumoniae. Molecular Medicine Reports 2016, 14(5):4030-4036.
Hu J, Ye Y, Chen X, Xiong L, Xie W, Liu P: Insight into the Pathogenic Mechanism of Mycoplasma pneumoniae. Current Microbiology 2022, 80(1).
Xu C, Luo L-Y, Wu B-C, Ding N, Jin S-J, Huang J-B, Chen Y-P: Diagnostic values of soluble triggering receptor expressed on myeloid cells (sTREM-1) and interferon-inducible protein-10 (IP-10) for severe mycoplasma pneumoniae pneumonia in children. Clinics 2024, 79.
Gudowska-Sawczuk M, Mroczko B: What Is Currently Known about the Role of CXCL10 in SARS-CoV-2 Infection? International Journal of Molecular Sciences 2022, 23(7).
Zhang N, Zhao YD, Wang XM: CXCL10 an important chemokine associated with cytokine storm in COVID-19 infected patients. Eur Rev Med Pharmacol Sci 2020, 24(13):7497-7505.
Li W, Liu Y-j, Zhao X-l, Shang S-q, Wu L, Ye Q, Xu H: Th1/Th2 Cytokine Profile and Its Diagnostic Value in Mycoplasma pneumoniae Pneumonia. Iranian Journal of Pediatrics 2016, 26(1).
Zhao J-l, Wang X, Wang Y-s: Relationships between Th1/Th2 cytokine profiles and chest radiographic manifestations in childhood<em> Mycoplasma pneumoniae</em> pneumonia. Therapeutics and Clinical Risk Management 2016, Volume 12:1683-1692.
Kurata S, Osaki T, Yonezawa H, Arae K, Taguchi H, Kamiya S: Role of IL-17A and IL-10 in the antigen induced inflammation model by Mycoplasma pneumoniae. BMC Microbiol 2014, 14:156.
Vazirinejad R, Ahmadi Z, Kazemi Arababadi M, Hassanshahi G, Kennedy D: The Biological Functions, Structure and Sources of CXCL10 and Its Outstanding Part in the Pathophysiology of Multiple Sclerosis. Neuroimmunomodulation 2014, 21(6):322-330.
Peperzak V, Veraar EAM, Xiao Y, Babala N, Thiadens K, Brugmans M, Borst J: CD8+ T Cells Produce the Chemokine CXCL10 in Response to CD27/CD70 Costimulation To Promote Generation of the CD8+ Effector T Cell Pool. The Journal of Immunology 2013, 191(6):3025-3036.

No competing interests reported.

WB.docx

Download PDF

Version 1

posted

You are reading this latest preprint version

The role of IFN-γ/CXCL10 axis in Mycoplasma pneumonia infection

Status:

Version 1

Abstract

Background

Methods

Results

Conclusions

Figures

Introduction

Methods

Patients

Diagnostic criteria

Exclusion criteria

Collection of clinical data

Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) analysis

Protein Chip

Cell culture

ELISA

Flow cytometry

Western blot

Transfection

Transwell assays

Statistical analysis

Results

Discussion

Abbreviations

Declarations

Consent for publication

Ethics statement

Conflict of interest

Funding

Author Contribution

Acknowledgement

Data Availability

References

Additional Declarations

Supplementary Files

Status:

Version 1